Chronic ketamine impairs fear conditioning and produces long-lasting reductions in auditory evoked potentials

Neurobiology of Disease

Volumn 35, Issue 2, 2009, Pages 311-317

  Amann, Laura C ^a   Halene, Tobias B ^a,b   Ehrlichman, Richard S ^a   Luminais, Stephen N ^a   Ma, Nan ^a   Abel, Ted ^a   Siegel, Steven J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Auditory evoked potential (AEP); Drug abuse; Event related potential (ERP); Fear conditioning; Gating; Ketamine; Schizophrenia

Indexed keywords

KETAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUDITORY STIMULATION; CONDITIONING; CONTROLLED STUDY; ELECTROENCEPHALOGRAPHY; EVOKED AUDITORY RESPONSE; FEAR; FOOTSHOCK; FREEZING; LATENT PERIOD; MALE; MEMORY DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSORY EVALUATION;

ACOUSTIC STIMULATION; ANALYSIS OF VARIANCE; ANIMALS; AUDITORY PERCEPTION; CONDITIONING, CLASSICAL; ELECTRODES, IMPLANTED; ELECTROSHOCK; EVOKED POTENTIALS, AUDITORY; EXCITATORY AMINO ACID ANTAGONISTS; FEAR; FREEZING REACTION, CATALEPTIC; HIPPOCAMPUS; KETAMINE; MALE; MICE; MICE, INBRED C57BL; PITCH DISCRIMINATION;

EID: 67649487924     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.05.012     Document Type: Article

References (64)

1. Amann L.C., Phillips J.M., et al. Male and female mice differ for baseline and nicotine-induced event related potentials. Behav. Neurosci. 122 5 (2008) 982-990
2. Berman R.M., Cappiello A., et al. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47 4 (2000) 351-354
3. Bissiere S., Plachta N., et al. The rostral anterior cingulate cortex modulates the efficiency of amygdala-dependent fear learning. Biol. Psychiatry 63 9 (2007) 821-831
4. Brockhaus-Dumke A., Schultze-Lutter F., et al. Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients. Biol. Psychiatry 64 5 (2008) 376-384
5. Brown K., Gordon E., et al. Misattribution of sensory input reflected in dysfunctional target:non-target ERPs in schizophrenia. Psychol. Med. 30 6 (2000) 1443-1449
6. Calzavara, M.B., Medrano, W.A., et al., in press. Neuroleptic drugs revert the contextual fear conditioning deficit presented by spontaneously hypertensive rats: a potential animal model of emotional context processing in schizophrenia? Schizophr. Bull. (Electronic publication ahead of print dated Feb. 16 2008).
7. Connolly P.M., Maxwell C.R., et al. Inhibition of auditory evoked potentials and prepulse inhibition of startle in DBA/2J and DBA/2Hsd inbred mouse substrains. Brain Res. 992 1 (2003) 85-95
8. Connolly P.M., Maxwell C., et al. The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components. Neurochem. Res. 29 6 (2004) 1179-1188
9. Covington J.W., and Polich J. P300, stimulus intensity, and modality. Electroencephalogr. Clin. Neurophysiol. 100 6 (1996) 579-584
10. Cvrcek P. Side effects of ketamine in the long-term treatment of neuropathic pain. Pain Med. 9 2 (2008) 253-257
11. Davalos D.B., Kisley M.A., et al. Mismatch negativity in detection of interval duration deviation in schizophrenia. NeuroReport 14 9 (2003) 1283-1286
12. Davis M., and Shi C. The amygdala. Curr. Biol. 10 4 (2000) R131
13. Ehrlichman R.S., Maxwell C.R., et al. Deviance-elicited changes in event-related potentials are attenuated by ketamine in mice. J. Cogn. Neurosci. 20 8 (2008) 1403-1414
14. Ford J.M., Roth W.T., et al. Failures of automatic and strategic processing in schizophrenia: comparisons of event-related brain potential and startle blink modification. Schizophr. Res. 37 2 (1999) 149-163
15. Frankland P.W., and Bontempi B. The organization of recent and remote memories. Nat. Rev., Neurosci. 6 2 (2005) 119-130
16. Fry A.F., and Hale S. Relationships among processing speed, working memory, and fluid intelligence in children. Biol. Psychol. 54 1-3 (2000) 1-34
17. Graves L.A., Heller E.A., et al. Sleep deprivation selectively impairs memory consolidation for contextual fear conditioning. Learn. Mem. 10 3 (2003) 168-176
18. Haenschel C., Vernon D.J., et al. Event-related brain potential correlates of human auditory sensory memory-trace formation. J. Neurosci. 25 45 (2005) 10494-10501
19. Heinrichs R.W., and Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12 3 (1998) 426-445
20. Javitt D.C. Intracortical mechanisms of mismatch negativity dysfunction in schizophrenia. Audiol. Neuro-Otol. 5 3-4 (2000) 207-215
21. Javitt D.C. Glutamate and schizophrenia: phencyclidine, N-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int. Rev. Neurobiol. 78 (2007) 69-108
22. Kannan T.R., Saxena A., et al. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J. Pain Symptom Manage 23 1 (2002) 60-65
23. Keene C.S., and Bucci D.J. Contributions of the retrosplenial and posterior parietal cortices to cue-specific and contextual fear conditioning. Behav. Neurosci. 122 1 (2008) 89-97
24. Krystal J.H., Karper L.P., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51 3 (1994) 199-214
25. LeDoux J.E. Emotion: clues from the brain. Annu. Rev. Psychol. 46 (1995) 209-235
26. Lindsley C.W., Shipe W.D., et al. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr. Top. Med. Chem. 6 8 (2006) 771-785
27. Majewski-Tiedeken C.R., Rabin C.R., et al. Ketamine exposure in adult mice leads to increased cell death in C3H, DBA2 and FVB inbred mouse strains. Drug Alcohol Depend 92 1-3 (2008) 217-227
28. Malhotra A.K., Pinals D.A., et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17 3 (1997) 141-150
29. Maren S. Neurobiology of Pavlovian fear conditioning. Annu. Rev. Neurosci. 24 (2001) 897-931
30. Matus-Amat P., Higgins E.A., et al. The role of dorsal hippocampus and basolateral amygdala NMDA receptors in the acquisition and retrieval of context and contextual fear memories. Behav. Neurosci. 121 4 (2007) 721-731
31. Maxwell C.R., Ehrlichman R.S., et al. Ketamine produces lasting disruptions in encoding of sensory stimuli. J. Pharmacol. Exp. Ther. 316 1 (2006) 315-324
32. Maxwell C.R., Kanes S.J., et al. Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications. Neuroscience 129 1 (2004) 101-107
33. Maxwell C.R., Liang Y., et al. Effects of chronic olanzapine and haloperidol differ on the mouse N1 auditory evoked potential. Neuropsychopharmacology 29 4 (2004) 739-746
34. May P., Tiitinen H., et al. Frequency change detection in human auditory cortex. J. Comput. Neurosci. 6 2 (1999) 99-120
35. Metzger K.L., Maxwell C.R., et al. Effects of nicotine vary across two auditory evoked potentials in the mouse. Biol. Psychiatry 61 1 (2007) 23-30
36. Michie P.T. What has MMN revealed about the auditory system in schizophrenia?. Int. J. Psychophysiol. 42 2 (2001) 177-194
37. Morgan C.J., Mofeez A., et al. Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 29 1 (2004) 208-218
38. Morgan C.J., Mofeez A., et al. Ketamine impairs response inhibition and is positively reinforcing in healthy volunteers: a dose-response study. Psychopharmacology (Berl) 172 3 (2004) 298-308
39. Newcomer J.W., Farber N.B., et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20 2 (1999) 106-118
40. Okon T. Ketamine: an introduction for the pain and palliative medicine physician. Pain Physician 10 3 (2007) 493-500
41. Ong J.C., Brody S.A., et al. An investigation of the efficacy of mood stabilizers in rodent models of prepulse inhibition. J. Pharmacol. Exp. Ther. 315 3 (2005) 1163-1171
42. Pedraz J.L., Lanao J.M., et al. Kinetics of ketamine and its metabolites in rabbits with normal and impaired renal function. Eur. J. Drug Metab. Pharmacokinet. 10 1 (1985) 33-39
43. Pietersen C.Y., Bosker F.J., et al. An animal model of emotional blunting in schizophrenia. PLoS ONE 2 12 (2007) e1360
44. Pietersen C.Y., Bosker F.J., et al. Ketamine administration disturbs behavioural and distributed neural correlates of fear conditioning in the rat. Prog. Neuropsychopharmacol. Biol. Psychiatry 30 7 (2006) 1209-1218
45. Pypendop B.H., and Ilkiw J.E. Pharmacokinetics of ketamine and its metabolite, norketamine, after intravenous administration of a bolus of ketamine to isoflurane-anesthetized dogs. Am. J. Vet. Res. 66 12 (2005) 2034-2038
46. Reuben S.S., and Buvanendran A. Preventing the development of chronic pain after orthopaedic surgery with preventive multimodal analgesic techniques. J. Bone Joint Surg. Am. 89 6 (2007) 1343-1358
47. Roth W.T., Pfefferbaum A., et al. Auditory event-related potentials in schizophrenia and depression. Psychiatry Res. 4 2 (1981) 199-212
48. Scallet A.C., Schmued L.C., et al. Developmental neurotoxicity of ketamine: morphometric confirmation, exposure parameters, and multiple fluorescent labeling of apoptotic neurons. Toxicol. Sci. 81 2 (2004) 364-370
49. Sheehan K.A., McArthur G.M., et al. Is discrimination training necessary to cause changes in the P2 auditory event-related brain potential to speech sounds?. Brain Res. Cogn. Brain Res. 25 2 (2005) 547-553
50. Shelley A.M., Silipo G., et al. Diminished responsiveness of ERPs in schizophrenic subjects to changes in auditory stimulation parameters: implications for theories of cortical dysfunction. Schizophr. Res. 37 1 (1999) 65-79
51. Shenton M.E., Faux S.F., et al. Clinical correlations of auditory P200 topography and left temporo-central deficits in schizophrenia: a preliminary study. J. Psychiatr. Res. 23 1 (1989) 13-34
52. Siegel S.J., Connolly P., et al. Effects of strain, novelty, and NMDA blockade on auditory-evoked potentials in mice. Neuropsychopharmacology 28 4 (2003) 675-682
53. Siegel S.J., Maxwell C.R., et al. Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials. Neuroscience 133 3 (2005) 729-738
54. Sinner B., and Graf B.M. Ketamine. Handb. Exp. Pharmacol. 182 (2008) 313-333
55. Slikker Jr. W., Zou X., et al. Ketamine-induced neuronal cell death in the perinatal rhesus monkey. Toxicol. Sci. 98 1 (2007) 145-158
56. Umbricht D., Vyssotki D., et al. Deviance-related electrophysiological activity in mice: is there mismatch negativity in mice?. Clin. Neurophysiol. 116 2 (2005) 353-363
57. Wang C., Sadovova N., et al. The role of the N-methyl-d-aspartate receptor in ketamine-induced apoptosis in rat forebrain culture. Neuroscience 132 4 (2005) 967-977
58. Winterer G., Egan M.F., et al. Event-related potentials and genetic risk for schizophrenia. Biol. Psychiatry 50 6 (2001) 407-417
59. Wunderlich J.L., and Cone-Wesson B.K. Effects of stimulus frequency and complexity on the mismatch negativity and other components of the cortical auditory-evoked potential. J. Acoust. Soc. Am. 109 4 (2001) 1526-1537
60. Yingling C.D., and Nethercut G.E. Evoked responses to frequency shifted tones: tonotopic and contextual determinants. Int. J. Neurosci. 22 1-2 (1983) 107-118
61. Young C., Jevtovic-Todorovic V., et al. Potential of ketamine and midazolam, individually or in combination, to induce apoptotic neurodegeneration in the infant mouse brain. Br. J. Pharmacol. 146 2 (2005) 189-197
62. Zanoveli J.M., Ferreira-Netto C., et al. Conditioned place aversion organized in the dorsal periaqueductal gray recruits the laterodorsal nucleus of the thalamus and the basolateral amygdala. Exp. Neurol. 208 1 (2007) 127-136
63. Zarate Jr. C.A., Singh J.B., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63 8 (2006) 856-864
64. Zou X., Patterson T.A., et al. Potential neurotoxicity of ketamine in the developing rat brain. Toxicol. Sci. 108 1 (2009) 149-158